VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | ZUMA-7 subgroup analysis: axi-cel vs SOC in elderly patients with R/R LBCL

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, comments on the outcomes of elderly patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) vs standard of care (SOC) from the ZUMA-7 study (NCT03391466). Dr Sureda highlights the superiority of axi-cel in this patient population in terms of efficacy, tolerability, as well as in terms of patient-reported outcomes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion
Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi
Speaker’s Bureau: Takeda
Research support: Takeda, BMS/Celgene

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter